Phage display enables machine learning discovery of cancer antigen-specific TCRs.

Journal: Science advances
Published Date:

Abstract

T cells targeting epitopes in infectious diseases or cancer play a central role in spontaneous and therapy-induced immune responses. Epitope recognition is mediated by the binding of the T cell receptor (TCR), and TCRs recognizing clinically relevant epitopes are promising for T cell-based therapies. Starting from a TCR targeting the cancer-testis antigen NY-ESO-1 epitope, we built large phage display libraries of TCRs with randomized complementary determining region 3 of the β chain. The TCR libraries were panned against NY-ESO-1, which enabled us to collect thousands of epitope-specific TCR sequences. Leveraging these data, we trained a machine learning TCR-epitope interaction predictor and identified several epitope-specific TCRs from TCR repertoires. Cellular assays revealed that the predicted TCRs displayed activity toward NY-ESO-1 and no detectable cross-reactivity. Our work demonstrates how display technologies combined with TCR-epitope interaction predictors can effectively leverage large TCR repertoires for TCR discovery.

Authors

  • Giancarlo Croce
    Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Rachid Lani
    Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
  • Delphine Tardivon
    Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
  • Sara Bobisse
    Agora Cancer Research Centre, Lausanne, Switzerland.
  • Mariastella de Tiani
    Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
  • Maiia Bragina
    Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Marta A S Perez
    Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Justine Michaux
    Agora Cancer Research Centre, Lausanne, Switzerland.
  • Hui Song Pak
    Agora Cancer Research Centre, Lausanne, Switzerland.
  • Alexandra Michel
    Agora Cancer Research Centre, Lausanne, Switzerland.
  • Talita Gehret
    Agora Cancer Research Centre, Lausanne, Switzerland.
  • Julien Schmidt
    Ludwig Institute for Cancer Research, University of Lausanne, 1066 Epalinges, Switzerland.
  • Philippe Guillame
    Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
  • Michal Bassani-Sternberg
    Agora Cancer Research Centre, Lausanne, Switzerland.
  • Vincent Zoete
    Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Alexandre Harari
    Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Nathalie Rufer
    Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
  • Michael Hebeisen
    Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
  • Steven M Dunn
    Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.
  • David Gfeller
    Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. david.gfeller@unil.ch.